Journal · Cancer immunotherapy · Updated 22 November 2026
Cancer Immunology, Immunotherapy
Read Cancer Immunology, Immunotherapy articles on DeepDyve. No university library needed.
Cancer Immunology, Immunotherapy covers how the immune system interacts with cancer and how treatments that harness it perform, from immune suppression inside tumors and RNA-based vaccine platforms to checkpoint inhibitors in liver, bladder and kidney cancer. Springer Nature publishes it. It was previously published as Cancer Immunology and Immunotherapy. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.
Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.
Personal plans aren’t for business use. Reading for work? See Enterprise.
Cancer Immunology, Immunotherapy at a glance
- Full title
- Cancer Immunology, Immunotherapy
- Former title
- Cancer Immunology and Immunotherapy
- Abbreviation (NLM)
- Cancer Immunol Immunother
- Publisher
- Springer Nature
- Print ISSN
- 0340-7004
- Online ISSN (eISSN)
- 1432-0851
- Current title since
- 1982
- Subjects
- Allergy and Immunology, Neoplasms, Therapeutics
- Access model
- Open access since 2024
Ways to access Cancer Immunology, Immunotherapy
All of the articles Cancer Immunology, Immunotherapy published from January 1 to November 20, 2026 are open access and free to read. For older articles, look for the authors’ manuscript, check a library, or read them on DeepDyve.
- Open access articles. 100% of Cancer Immunology, Immunotherapy articles published from January 1 to November 20, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
- The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
- Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
- NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
- A library. Your university, hospital or public library may subscribe to Cancer Immunology, Immunotherapy. Check its journal list and whether it offers remote access.
- DeepDyve. Read Cancer Immunology, Immunotherapy articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.
Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.
Impact factor and metrics
Cancer Immunology, Immunotherapy’s 2025 Journal Impact Factor is 5.8, and its 5-year Impact Factor is 5.6.
5.8
Journal Impact Factor (2025)
5.6
5-year Impact Factor (2025)
2 days
Median time to first decision
2.3M
Downloads (2025)
Source: journal metrics on the Cancer Immunology, Immunotherapy homepage (Springer Nature), checked November 22, 2026. Impact Factor from Clarivate Journal Citation Reports.
Recent Cancer Immunology, Immunotherapy research worth reading
Published February to April 2026. Summaries describe what the authors report.
-
CD39/CD73-mediated immunosuppression and tumor aggressiveness in bladder cancer
In 39 patients with bladder cancer and 14 healthy controls, the authors report widespread immunosuppression linked to CD39 and CD73, and found that circulating CD8+CD39+ and CD8+CD73+ T cells distinguished high-grade tumors with moderate accuracy (AUC > 0.70).
Furriel et al. · Cancer Immunology, Immunotherapy, published online April 22, 2026 · DOI 10.1007/s00262-026-04400-4
-
Circular RNAs in cancer: Its biogenesis, functions, relationships with cancer progression, applications in immunotherapy and biomarker potentials
In a review, the authors summarize how circular RNAs form and drive cancer progression, how they shape responses to checkpoint blockade and serve as platforms for cancer vaccines and CAR-T therapy, and their potential as noninvasive biomarkers.
Gao et al. · Cancer Immunology, Immunotherapy, published online March 31, 2026 · DOI 10.1007/s00262-025-04176-z
-
Comparative efficacy of combination regimens based on interventional therapy and immune checkpoint inhibitors (ICIs) in patients with intermediate- and advanced-stage hepatocellular carcinoma: a systematic review, meta-analysis, and network meta-analysis
Pooling 45 studies with 4,738 patients and 14 regimens in hepatocellular carcinoma, the authors report that TACE plus a tyrosine-kinase inhibitor and tislelizumab gave a median progression-free survival of 11.7 months, while the toripalimab combination ranked first for overall survival.
Su et al. · Cancer Immunology, Immunotherapy, published online February 7, 2026 · DOI 10.1007/s00262-025-04251-5
-
Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV)
In a real-world study of 1918 patients across 79 centers in 21 countries, the authors report that those with squamous differentiation had shorter median overall survival than those with pure urothelial carcinoma on avelumab, pembrolizumab or enfortumab vedotin.
Mollica et al. · Cancer Immunology, Immunotherapy, published online March 24, 2026 · DOI 10.1007/s00262-026-04328-9
-
Pattern of disease recurrence and outcomes after progression of high-risk renal cell carcinoma (RCC) patients treated with adjuvant immunotherapy
Among 70 patients with high-risk renal cell carcinoma given adjuvant immunotherapy after surgery, the authors report that 15 (21%) relapsed, mostly with oligometastatic disease, and that 30-month disease-free and overall survival rates were 74% and 94%.
Ciccarese et al. · Cancer Immunology, Immunotherapy, published online February 25, 2026 · DOI 10.1007/s00262-026-04331-0
See every Cancer Immunology, Immunotherapy article on DeepDyve
Related journals
Questions about Cancer Immunology, Immunotherapy
How can I read Cancer Immunology, Immunotherapy articles without a subscription?
100% of Cancer Immunology, Immunotherapy articles published from January 1 to November 20, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Cancer Immunology, Immunotherapy articles online for $59 a month or $499 a year after a free first month.
What is the abbreviation for Cancer Immunology, Immunotherapy?
Cancer Immunology, Immunotherapy’s NLM (PubMed) abbreviation is Cancer Immunol Immunother.
What is the ISSN of Cancer Immunology, Immunotherapy?
The print ISSN is 0340-7004 and the online ISSN is 1432-0851.
What is the impact factor of Cancer Immunology, Immunotherapy?
Cancer Immunology, Immunotherapy’s Journal Impact Factor is 5.8 (2025), and its 5-year Impact Factor is 5.6, according to Springer Nature’s published metrics.
Is Cancer Immunology, Immunotherapy open access?
Yes. Cancer Immunology, Immunotherapy has published open access since 2024: 352 of the 352 articles it published from January 1 to November 20, 2026 carry a Creative Commons license, per Crossref.
Cancer Immunology, Immunotherapy articles on DeepDyve are licensed from Springer Nature. Journal facts as of 22 November 2026.
Start reading Cancer Immunology, Immunotherapy today
One month free, then less than $2 a day. Cancer Immunology, Immunotherapy, plus millions of articles from thousands of journals.






